Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516353 | 0.91 | ACVRL1 (0.33) | HSD11B1TRPV1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13674544 | 0.91 | ACVRL1 (0.33) | HSD11B1TRPV1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13675467 | 0.82 | HSD11B1 (0.39) | HSD11B1ROCK2 | |
| SCHEMBL13675549 | 0.82 | HSD11B1 (0.41) | HSD11B1ROCK2 | |
| SCHEMBL13675620 | 0.80 | HSD11B1 (0.39) | HSD11B1ROCK2 | |
| SCHEMBL13675572 | 0.79 | KMT2A (0.35) | HSD11B1ALDH1A1KDM4EMAPTROCK2 | |
| SCHEMBL4519319 | 0.79 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL4504541 | 0.79 | ALDH1A1 (0.36) | HSD11B1ALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL13675523 | 0.77 | DPP4 (0.37) | HSD11B1 | |
| SCHEMBL13675573 | 0.77 | MCHR1 (0.37) | HSD11B1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885TRPV1 3739/4885ALDH1A1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.